Cangrelor Intravenous Administration for PCI Ischemic Event Reduction
Solution Overview
Problem
Current antiplatelet therapies for patients undergoing percutaneous coronary intervention (PCI) face challenges such as delayed onset of action, variable bioavailability, and increased bleeding risks, particularly with oral P2Y12 inhibitors like clopidogrel, which are not effective in urgent situations and may lead to ischemic events like stent thrombosis and myocardial infarction.
Innovation Solution
Administration of cangrelor, a reversible and fast-acting adenosine triphosphate analogue inhibitor of the P2Y12 ADP receptor, which can be given intravenously as a bolus and infusion to quickly inhibit platelets with minimal bleeding risk, potentially combined with other therapeutic agents like clopidogrel or bivalirudin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If oral P2Y12 inhibitors like clopidogrel are administered, then antiplatelet effect is achieved, but onset of action is delayed
Solution Approach 1:
The patent replaces oral administration (mechanical swallowing and gastrointestinal absorption) with intravenous administration (direct injection into bloodstream). This substitution eliminates the delayed absorption phase, achieving immediate antiplatelet effect while maintaining reliability through direct delivery of the active drug to systemic circulation.
Solution Approach 2:
The patent changes the route of administration parameter from oral to intravenous, which fundamentally alters the pharmacokinetic profile. This parameter change results in immediate bioavailability and rapid onset of action, resolving the contradiction between speed and reliability of antiplatelet effect.
2Reliability
If oral P2Y12 inhibitors are administered, then antiplatelet therapy is provided, but bioavailability is variable
Solution Approach 1:
The patent substitutes oral administration with intravenous administration, eliminating the variable gastrointestinal absorption process. This substitution ensures consistent and predictable bioavailability by delivering the drug directly into the bloodstream, where 100% bioavailability is achieved regardless of patient gastrointestinal conditions.
3Reliability
If potent oral ADP blockers are administered, then ischemic outcomes are reduced, but bleeding rates increase
Solution Approach 1:
The patent employs a dynamic dosing strategy with intravenous cangrelor that allows for rapid titration and adjustment based on patient response and procedural needs. The short half-life of cangrelor enables quick termination of antiplatelet effect if bleeding occurs, providing temporal dynamics that balance ischemic protection with bleeding risk management.
Solution Approach 2:
The patent uses intravenous cangrelor as an intermediary agent that provides potent and reversible platelet inhibition during the critical periprocedural period. This intermediary approach allows for controlled, temporary intensification of antiplatelet therapy without the cumulative and irreversible effects of oral P2Y12 inhibitors, thereby reducing bleeding complications while maintaining ischemic event prevention.
4Speed
If clopidogrel is administered prior to angiographic definition, then platelet inhibition is achieved, but perioperative bleeding risk increases
Solution Approach 1:
The patent utilizes the dynamic pharmacokinetic properties of intravenous cangrelor with its short half-life to provide timely platelet inhibition when needed, with the ability to rapidly discontinue the drug if surgical intervention becomes necessary. This temporal control allows for flexible management of bleeding risk while achieving the desired timing of antiplatelet effect.
Solution Approach 2:
The patent changes the administration route from oral to intravenous and adjusts the dosing regimen to provide controlled, reversible platelet inhibition. This parameter change enables precise temporal control over the intensity and duration of antiplatelet effect, allowing clinicians to achieve rapid inhibition while minimizing perioperative bleeding risk through easy reversibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cangrelor effectively reduces the incidence and prevents ischemic events like stent thrombosis and myocardial infarction during and after PCI without significantly increasing severe bleeding or the need for transfusions, offering rapid and consistent platelet inhibition with normalization of platelet function post-treatment.
Implementation Method 1
cangrelor, a reversible and fast-acting adenosine triphosphate analogue inhibitor of the P2Y12 ADP receptor
Data Source
AI summary
Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.